[go: up one dir, main page]

WO2012108794A3 - 1,2,4-triazol-3-ylthioglycolic acid derivatives for use in therapy - Google Patents

1,2,4-triazol-3-ylthioglycolic acid derivatives for use in therapy Download PDF

Info

Publication number
WO2012108794A3
WO2012108794A3 PCT/RU2012/000085 RU2012000085W WO2012108794A3 WO 2012108794 A3 WO2012108794 A3 WO 2012108794A3 RU 2012000085 W RU2012000085 W RU 2012000085W WO 2012108794 A3 WO2012108794 A3 WO 2012108794A3
Authority
WO
WIPO (PCT)
Prior art keywords
triazol
therapy
acid derivatives
ylthioglycolic
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2012/000085
Other languages
French (fr)
Russian (ru)
Other versions
WO2012108794A2 (en
Inventor
Андрей Александрович ВИННИК
Петр Олегович ФЕДИЧЕВ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2012108794A2 publication Critical patent/WO2012108794A2/en
Publication of WO2012108794A3 publication Critical patent/WO2012108794A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to 1,2,4-triazol-3-ylglycolic acid derivatives and to pharmaceutically acceptable salts, salt adducts or solvates thereof, and also to pharmaceutical compositions containing said derivatives, for use in therapy.
PCT/RU2012/000085 2011-02-10 2012-02-10 1,2,4-triazol-3-ylthioglycolic acid derivatives for use in therapy Ceased WO2012108794A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2011104686/04A RU2011104686A (en) 2011-02-10 2011-02-10 DERIVATIVES OF 1,2,4-TRIAZOL-3-ILTIOGLYCLOLIC ACID FOR USE IN THERAPY
RU2011104686 2011-02-10

Publications (2)

Publication Number Publication Date
WO2012108794A2 WO2012108794A2 (en) 2012-08-16
WO2012108794A3 true WO2012108794A3 (en) 2012-10-26

Family

ID=46639113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2012/000085 Ceased WO2012108794A2 (en) 2011-02-10 2012-02-10 1,2,4-triazol-3-ylthioglycolic acid derivatives for use in therapy

Country Status (2)

Country Link
RU (1) RU2011104686A (en)
WO (1) WO2012108794A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2626003C2 (en) * 2014-04-28 2017-07-21 Общество с ограниченной ответственностью "Квантум Фармасьютикалс" 1,2,4-triazol-3-ylthioglycolic acid amide with antiviral activity or its pharmaceutically acceptable salts, pharmaceutical compositions, and their application for flu treatment and prevention

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4564622A (en) * 1982-10-21 1986-01-14 Bayer Aktiengesellschaft Triazole derivative as an antiviral agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4564622A (en) * 1982-10-21 1986-01-14 Bayer Aktiengesellschaft Triazole derivative as an antiviral agent

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Synthesis of 5-Aryl-2H-tetrazoles, 5-Aryl-2H-tetrazole-2-acetic Acids, and [(4-Phenyl-5-aryl-4H-1,2,4-triazol-3-yl)thio]acetic Acids as Possible Superoxide Scavengers and Antiinflammatory Agents.", J. MED. CHEM., vol. 27, 1984, pages 1565 - 1570 *
DATABASE ACS 10 March 2003 (2003-03-10), accession no. 97241-42-6 *
DATABASE ACS 11 October 2001 (2001-10-11), accession no. 61476-68-8 *
DATABASE ACS 12 March 2003 (2003-03-12), accession no. 97950-94-4 *
DATABASE ACS 14 March 2003 (2003-03-14), accession no. 99115-95-6 *
DATABASE ACS 17 November 2000 (2000-11-17), accession no. 03103-18-6 *
DATABASE ACS 17 November 2000 (2000-11-17), accession no. 03105-40-0 *
DATABASE ACS 19 April 2002 (2002-04-19), accession no. 06203-05-2 *
DATABASE ACS 19 January 2001 (2001-01-19), accession no. 15231-27-7 *
DATABASE ACS 20 November 2000 (2000-11-20), accession no. 03203-30-7 *
DATABASE ACS 20 November 2000 (2000-11-20), accession no. 03207-53-6 *
DATABASE ACS 5 December 2000 (2000-12-05), accession no. 06757-40-4 *

Also Published As

Publication number Publication date
RU2011104686A (en) 2012-08-20
WO2012108794A2 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
SA515360469B1 (en) Heterocyclic compounds for inhibiting glutaminase and their methods of use
WO2013188783A8 (en) Deuterated derivatives of ruxolitinib
UA109868C2 (en) N -alkyltriazole compounds asr
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
EA201590371A1 (en) 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS
PH12014500386A1 (en) Combination treatment for hepatitis c
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2013004995A8 (en) Pyrimidinone compounds and their use
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
MX348823B (en) Stable formulations of linaclotide.
HK1206028A1 (en) Phenicol antibacterials
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
WO2013040227A3 (en) Therapeutic compounds
MX340574B (en) Imidazo pyrazines.
MX2014013664A (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexy l) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide.
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
WO2015002755A3 (en) Compounds for the treatment of malaria
WO2013155465A8 (en) Substituted xanthine derivatives
AU2012360910A8 (en) Quinazolinone derivatives as HCV inhibitors
EA201500446A1 (en) PHARMACEUTICAL COMPOSITION TO REDUCE N-OXIDE TRIMETYLAMINE LEVEL
WO2012108794A3 (en) 1,2,4-triazol-3-ylthioglycolic acid derivatives for use in therapy
MX342465B (en) METHODS OF TREATING HEMATOLOGIC MALIGNANCIES USING 6-CYCLOHEXYL-1-HYDROXY-4-METHYL-2(1<i>H</i>)-PYRIDONE.
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
IL238071B (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12744535

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12744535

Country of ref document: EP

Kind code of ref document: A2